Phase 3 Trial of Semaglutide in Metabolic Dysfunction–Associated Steatohepatitis

Abstract

In patients with MASH and moderate or advanced liver fibrosis, once-weekly semaglutide at a dose of 2.4 mg improved liver histologic results. (Funded by Novo Nordisk; ClinicalTrials.gov number, NCT04822181.).